-
1 Comment
Puma Biotechnology, Inc is currently in a long term downtrend where the price is trading 22.5% below its 200 day moving average.
From a valuation standpoint, the stock is 99.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.8.
Puma Biotechnology, Inc's total revenue sank by 16.5% to $53M since the same quarter in the previous year.
Its net income has dropped by 33.9% to $-15M since the same quarter in the previous year.
Finally, its free cash flow fell by 1116.1% to $-16M since the same quarter in the previous year.
Based on the above factors, Puma Biotechnology, Inc gets an overall score of 1/5.
| Sector | Healthcare |
|---|---|
| Industry | Biotechnology |
| Exchange | NASDAQ |
| CurrencyCode | USD |
| ISIN | US74587V1070 |
| PE Ratio | 4.85 |
|---|---|
| Target Price | 4.3333 |
| Market Cap | 149M |
| Beta | 1.33 |
| Dividend Yield | None |
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds, as well as sub-license agreements with Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for PBYI using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
